Related Experiment Videos
Omalizumab: where does it fit into current asthma management?
Todd E Rambasek1, David M Lang, Mani S Kavuru
1Section of Allergy and Immunology, Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation, OH 44195, USA.
Cleveland Clinic Journal of Medicine
|April 2, 2004
Summary
Omalizumab (Xolair) is a promising monoclonal antibody for severe allergic asthma. It blocks allergic reactions but isn't a first-line treatment due to cost and data limitations.
Area of Science:
- Immunology
- Pulmonology
- Pharmacology
Background:
- Allergic asthma affects millions, often inadequately controlled by standard therapies.
- The allergic cascade involves complex immune responses.
- Current treatments may not address underlying allergic mechanisms effectively.
Purpose of the Study:
- To review the mechanism of action of omalizumab (Xolair).
- To identify patient candidates for omalizumab therapy.
- To discuss practical considerations for omalizumab use in allergic asthma management.
Main Methods:
- Literature review of clinical trials and pharmacological data.
- Analysis of omalizumab's role in blocking IgE-mediated allergic responses.
- Evaluation of treatment guidelines and real-world usage.
Main Results:
- Omalizumab effectively reduces exacerbations in moderate-to-severe persistent allergic asthma.
- It targets the allergic cascade by inhibiting IgE.
- Patient selection is crucial, considering disease severity and phenotype.
Conclusions:
- Omalizumab represents a significant advancement for specific allergic asthma populations.
- It is a valuable option when conventional therapies fail.
- Careful patient selection and monitoring are essential for optimal outcomes.